Source comparison
TB-500 Safety Studies: [Type] Comparison
Equine Veterinary Trials Thoroughbred racehorses with tendon injuries Accelerated healing, reduced inflammation at 10–20mg weekly doses over 8 weeks No acute toxicity observed; long-term follow-up limited to 6 months Most robust non-human data available. But c
This comparison does not assign a generated winner or score.
- Equine Veterinary Trials
- Thoroughbred racehorses with tendon injuries
- Accelerated healing, reduced inflammation at 10–20mg weekly doses over 8 weeks
- No acute toxicity observed; long-term follow-up limited to 6 months
- Most robust non-human data available. But cross-species pharmacokinetics differ significantly
- Rodent Cardiac Repair Models
- Mice with induced myocardial infarction
- Reduced scar tissue, improved ejection fraction, upregulated VEGF expression
- Theoretical angiogenesis dysregulation. Not evaluated in cancer-prone models
- Promising mechanism confirmation, but sample sizes small (n=12–24 per group) and short duration
- In Vitro Cell Migration Studies
- Human fibroblast and endothelial cell lines
- Thymosin beta-4 increased cell motility by 40–60% vs control in wound-healing assays
- None in controlled cell culture. Mechanism unclear in complex tissue environments
- Proves molecular mechanism but provides no systemic safety data
- Human Doping Case Reports
- Athletes detected with TB-500 metabolites in urine
- Confirmed human use; no systematic adverse event tracking performed
- Unknown. Cases identified retrospectively without health monitoring
- Evidence of use, not evidence of safety